Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yiguo Hu

Showing results (41-50 of 59) with videos related to

Pageof 6
Sort By:
Bioactive Materials|October 3, 2022
HDAC I/IIb selective inhibitor Purinostat Mesylate combined with GLS1 inhibition effectively eliminates CML stem cellsQiang Qiu, Linyu Yang, Yunyu Feng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 25, 2011
Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomideLoredana Santo, Teru Hideshima, Diana Cirstea, et al.
Signal Transduction and Targeted Therapy|February 28, 2023
TSPAN32 suppresses chronic myeloid leukemia pathogenesis and progression by stabilizing PTENQiang Qiu, Yuanyuan Sun, Linyu Yang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2019
Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of <i>BCR-ABL</i>-Induced B-Cell Acute Lymphoblastic LeukemiaLinyu Yang, Qiang Qiu, Minghai Tang, et al.
Blood|April 13, 2010
A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myelomaGüllü Görgün, Elisabetta Calabrese, Teru Hideshima, et al.
The Journal of Clinical Endocrinology and Metabolism|January 11, 2021
Novel Recurrent Altered Genes in Chinese Patients With Anaplastic Thyroid CancerLingyun Zhang, Zhixiang Ren, Zhengzheng Su, et al.
Signal Transduction and Targeted Therapy|June 25, 2025
Preclinical and first-in-human of purinostat mesylate, a novel selective HDAC I/IIb inhibitor, in relapsed/refractory multiple myeloma and lymphomaLinyu Yang, Qiang Qiu, Jie Wang, et al.
Cell Stem Cell|October 22, 2021
Differential m<sup>6</sup>A RNA landscapes across hematopoiesis reveal a role for IGF2BP2 in preserving hematopoietic stem cell functionRong Yin, Jiwei Chang, Yashu Li, et al.
Blood Advances|September 30, 2021
ALCAM-EGFR interaction regulates myelomagenesisHongmei Luo, Dan Zhang, Fangfang Wang, et al.
Nature Communications|July 25, 2022
Pancreatic tumor eradication via selective Pin1 inhibition in cancer-associated fibroblasts and T lymphocytes engagementJiaye Liu, Yang Wang, Chunyang Mu, et al.
Pageof 6

Showing results (41-50 of 59) with videos related to

Sort By:
Pageof 6
Bioactive Materials|October 3, 2022
HDAC I/IIb selective inhibitor Purinostat Mesylate combined with GLS1 inhibition effectively eliminates CML stem cellsQiang Qiu, Linyu Yang, Yunyu Feng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 25, 2011
Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomideLoredana Santo, Teru Hideshima, Diana Cirstea, et al.
Signal Transduction and Targeted Therapy|February 28, 2023
TSPAN32 suppresses chronic myeloid leukemia pathogenesis and progression by stabilizing PTENQiang Qiu, Yuanyuan Sun, Linyu Yang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2019
Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of <i>BCR-ABL</i>-Induced B-Cell Acute Lymphoblastic LeukemiaLinyu Yang, Qiang Qiu, Minghai Tang, et al.
Blood|April 13, 2010
A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myelomaGüllü Görgün, Elisabetta Calabrese, Teru Hideshima, et al.
The Journal of Clinical Endocrinology and Metabolism|January 11, 2021
Novel Recurrent Altered Genes in Chinese Patients With Anaplastic Thyroid CancerLingyun Zhang, Zhixiang Ren, Zhengzheng Su, et al.
Signal Transduction and Targeted Therapy|June 25, 2025
Preclinical and first-in-human of purinostat mesylate, a novel selective HDAC I/IIb inhibitor, in relapsed/refractory multiple myeloma and lymphomaLinyu Yang, Qiang Qiu, Jie Wang, et al.
Cell Stem Cell|October 22, 2021
Differential m<sup>6</sup>A RNA landscapes across hematopoiesis reveal a role for IGF2BP2 in preserving hematopoietic stem cell functionRong Yin, Jiwei Chang, Yashu Li, et al.
Blood Advances|September 30, 2021
ALCAM-EGFR interaction regulates myelomagenesisHongmei Luo, Dan Zhang, Fangfang Wang, et al.
Nature Communications|July 25, 2022
Pancreatic tumor eradication via selective Pin1 inhibition in cancer-associated fibroblasts and T lymphocytes engagementJiaye Liu, Yang Wang, Chunyang Mu, et al.
Pageof 6